Qnexa FDA Review Leaves Vivus Weak

The US Food and Drug Administration (FDA)'s Advisory Committee On Endocrinology And Metabolic Drugs has determined that Vivus's weight loss drug Qnexa should not be granted marketing approval on October 28 2010, when the agency's final decision is

To read the full article, please choose one of the following options: